Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos and Bayer Enter Target Discovery Collaboration

NEW YORK, Dec. 16 (GenomeWeb News) - Galapagos Genomics has entered into a collaboration with Bayer HealthCare to discover and validate novel drug targets, Galapagos said today.

Galapagos will design cellular assays in disease areas of interest to Bayer, and then use its SilenceSelect collection of adenoviruses with siRNA based knock-down sequences, along with its FLeXSelect collection of adenoviruses with full-length genes from druggable gene classes, to identify and validate targets.

Bayer has the exclusive right to select validated targets for drug development in return for upfront payments, research funding, and milestones. Further financial terms were not disclosed.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.